Dr Reddys Stock Analysis

RDY
 Stock
  

USD 53.88  0.26  0.48%   

The modest gains experienced by current holders of Dr Reddys Laboratories created some momentum for investors as it was traded today as low as 53.5 and as high as 54.02 per share. The company directors and management have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.75. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Additionally, take a look at Your Equity Center.
  
The Dr Reddys stock analysis report makes it easy to digest most publicly released information about Dr Reddys and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Dr Reddys Stock analysis module also helps to analyze the Dr Reddys price relationship with some important fundamental indicators such as market cap and management efficiency.

Dr Reddys Stock Analysis Notes

The company has price-to-book ratio of 0.05. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Dr Reddys Laboratories has Price/Earnings To Growth (PEG) ratio of 0.68. The entity last dividend was issued on the 8th of July 2021. The firm had 2:1 split on the 7th of September 2006. Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people. To find out more about Dr Reddys Laboratories contact MARC KIKUCHI at 91 40 4900 2900 or learn more at https://www.drreddys.com.

Dr Reddys Laboratories Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Dr Reddys' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Dr Reddys Laboratories or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
On 12th of August 2022 Dr Reddys paid $ 0.3784 per share dividend to its current shareholders
Latest headline from www.business-standard.com: US Stocks surge on easing inflation concerns - Business Standard

Dr Reddys Laboratories Upcoming and Recent Events

Earnings reports are used by Dr Reddys to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dr Reddys previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of February 2017
Next Financial Report11th of May 2017
Next Fiscal Quarter End31st of December 2016
Next Fiscal Year End11th of May 2017
Last Quarter Report30th of September 2016
Last Financial Announcement31st of December 2015

Dr Reddys Largest EPS Surprises

Earnings surprises can significantly impact Dr Reddys' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2005-07-26
2005-06-300.060.05-0.0116 
2020-07-29
2020-06-300.520.46-0.0611 
2013-05-14
2013-03-310.540.60.0611 
View All Earnings Estimates

Dr Reddys Thematic Classifications

In addition to having Dr Reddys stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare
Companies that count on Obamacare to take off

Dr Reddys Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Dr Reddys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dr Reddys Laboratories backward and forwards among themselves. Dr Reddys' institutional investor refers to the entity that pools money to purchase Dr Reddys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Royal Bank Of CanadaCommon Shares3.2 M179.1 M
Renaissance Technologies LlcCommon SharesM112.9 M
Blackrock IncCommon Shares1.6 M89.3 M
Vanguard Group IncCommon Shares1.1 M60.2 M
Morgan StanleyCommon Shares999.8 K55.4 M
State Street CorpCommon Shares766.8 K42.5 M
Dimensional Fund Advisors LpCommon Shares765.1 K42.4 M
Note, although Dr Reddys' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Dr Reddys Market Capitalization

The company currently falls under 'Mid-Cap' category with total capitalization of 8.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dr Reddys's market, we take the total number of its shares issued and multiply it by Dr Reddys's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Dr Reddys Profitablity

Dr Reddys' profitability indicators refer to fundamental financial ratios that showcase Dr Reddys' ability to generate income relative to its revenue or operating costs. If, let's say, Dr Reddys is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Dr Reddys' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Dr Reddys' profitability requires more research than a typical breakdown of Dr Reddys' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 13.68 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 21.63 %, which entails that for every 100 dollars of revenue, it generated 0.22 of operating income.

Management Efficiency

The entity has Return on Asset of 7.81 % which means that on every $100 spent on asset, it made $7.81 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.71 %, implying that it generated $15.71 on every 100 dollars invested. Dr Reddys management efficiency ratios could be used to measure how well dr reddys laboratories manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 16th of August 2022, Dr Reddys owns the Standard Deviation of 1.73, downside deviation of 1.57, and Market Risk Adjusted Performance of 0.3517. In respect to fundamental indicators, the technical analysis model provides you with a way to check possible technical drivers of Dr Reddys Laboratories, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Dr Reddys, which can be compared to its peers in the sector. Please confirm Dr Reddys Laboratories standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Dr Reddys Laboratories is priced favorably, providing market reflects its prevailing price of 53.88 per share. Given that Dr Reddys Laboratories has jensen alpha of 0.1049, we urge you to verify Dr Reddys's latest market performance to make sure the company can sustain itself in the future.

Dr Reddys Laboratories Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Dr Reddys Laboratories price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Dr Reddys Predictive Daily Indicators

Dr Reddys intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dr Reddys stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Dr Reddys Forecast Models

Dr Reddys time-series forecasting models is one of many Dr Reddys' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dr Reddys' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Dr Reddys Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dr Reddys prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dr Reddys shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Dr Reddys. By using and applying Dr Reddys Stock analysis, traders can create a robust methodology for identifying Dr Reddys entry and exit points for their positions.
Dr. Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients , Proprietary Products, and Others segments. The companys Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Current Dr Reddys Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dr Reddys analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dr Reddys analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
48.95Hold2Odds
Dr Reddys Laboratories current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Dr Reddys analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dr Reddys stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dr Reddys Laboratories, talking to its executives and customers, or listening to Dr Reddys conference calls.
Dr Reddys Analyst Advice Details

Dr Reddys Stock Analysis Indicators

Dr Reddys Laboratories stock analysis indicators help investors evaluate how Dr Reddys stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dr Reddys shares will generate the highest return on investment. By understating and applying Dr Reddys stock analysis, traders can identify Dr Reddys position entry and exit signals to maximize returns.
Quick Ratio1.23
Trailing Annual Dividend Rate25.00
Fifty Two Week Low47.88
Revenue Growth6.00%
Payout Ratio17.63%
Average Daily Volume Last 10 Day153.84k
Shares Short Prior Month1.77M
Average Daily Volume In Three Month202.52k
Earnings Growth107.90%
Shares Percent Shares Out0.78%
Earnings Quarterly Growth108.10%
Gross Margins52.52%
Forward Price Earnings17.55
Float Shares116.92M
Fifty Two Week High67.76
Fifty Day Average54.57
Enterprise Value To Ebitda-0.03
Two Hundred Day Average56.92
Enterprise Value To Revenue-0.01
Trailing Annual Dividend Yield46.62%
Additionally, take a look at Your Equity Center. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Dr Reddys Stock analysis

When running Dr Reddys Laboratories price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know Dr Reddys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
1.08
Market Capitalization
8.9 B
Quarterly Revenue Growth YOY
0.06
Return On Assets
0.0781
Return On Equity
0.16
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of Dr Reddys that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine Dr Reddys value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.